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1 Introduction 
This is a uniquely human disease, with impairments in abstract reason­
ing and judgment. We've cured mice engineered with this disease over 
500 times. The mouse models don't translate into humans. We know for a 
fact that mice don't write books. 
HOWARD FILLIT, Chief Science Officer, Alzheimer's Drug Discovery Foundation, 
in Shakoor et al., 2017 
Perhaps the most impactful and foreboding development in chronic diseas­
es in recent decades has been the increasing prevalence and awareness of 
dementia. The various dementias, especially Alzheimer disease (AD), have de­
railed and ended the lives of tens of millions in America and worldwide. It is 
a truism that AD patients die twice. First the mind dies, and only later does 
the body. AD uniquely and unremittingly affects not only patients, but their 
families, caregivers, and communities. In recent years, AD may have displaced 
cancer as the most feared disease among Americans. As with other diseases 
that have no meaningful methods for prevention and treatment, research tar­
geting AD has primarily focused on preclinical approaches, predominantly us­
ing animals. Nonetheless, decades of animal research have failed to translate 
into significant advances in the prevention or treatment of AD. In view of this 
failure, a different and human-relevant approach is critically needed. 
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This chapter addresses the epidemiology and current understanding of AD 
as a scientific and societal challenge, reviews the uses and results of animal 
research in basic science and drug development, and discusses risk factors and 
funding. Important follow-up topics, including current and in-development, 
human-relevant approaches for replacement of the failed animal research par­
adigm, deserve comparable treatment and hence are not addressed here. The 
reader is referred to the list of recommended readings at the end of the chapter 
for further discussion of these topics. 
The ethics of continued use of the animal-based approach in AD is trouble­
some in at least two respects. First, regardless of where one stands on the ethi­
cal spectrum of animal use for medical research, certainly the inhumane and 
lethal use of animals for demonstrably faulty research is unethical. Second, the 
ethical responsibility to AD patients, their families, and the larger community 
demands reliable and useful results, which in tum demand a revised research 
approach, emphasizing human-relevant methods. 
2 Epidemiology and Current Status 
Dementia can be defined as a disorder of mental capabilities caused by brain 
disease or injury and marked by memory disorders, impaired thought and 
reasoning, diminished judgment, social withdrawal, and altered personality. 
Except for several reversible causes, dementia is a chronic and unremitting 
disease with a fatal outcome. AD is the most common form of dementia, ac­
counting for 60%-80% of all dementia diagnoses in the United States (us) 
(Alzheimer's Association, 2017). The next four most prevalent categories of 
dementia (vascular dementia, dementia with Lewy bodies, frontotemporal 
dementia, and mixed dementia) account for all but a small percentage of the 
other diagnoses. Vascular and mixed dementia overlap considerably with AD; 
nearly all cases of vascular dementia display characteristics of AD (Thal, Grin­
berg and Attems, 2012 ), and prevalence figures do not include the AD precur­
sor, mild cognitive impairment (Mc I), making the percentage of dementia and 
incipient dementia attributable to AD even higher (Lopez et al., 2012; Mitchell 
and Shiri-Feshki, 2009; Roberts et al., 2014a; Ward et al., 2013). AD prevalence 
increases with age and varies based on diagnostic criteria and death records. 
It can only be definitively diagnosed by postmortem examination of the brain, 
though recent advances in neuroimaging and cerebrospinal fluid analysis of­
fer strong clinical evidence and presumptive diagnosis. AD is almost certainly 
underdiagnosed and underreported, both among persons who die of AD and 
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those who die with AD (James et al., 2014; Taylor et al., 2017; Wachterman, Kiely 
and Mitchell, 2008; Weuve et al., 2014). 
A reasonable estimate of AD prevalence in the us is 3°/o of persons aged 
65-74 years, 17°/o of persons aged 75-84 years, and 32% of persons aged 85 
years and older (Hebert et al., 2013), though some sources estimate the risk for 
persons 85 years and older as nearly 50% (Alzheimer's Association, 2012; Chai, 
2007; Gatz et al., 2006). About 5.5 million Americans ( two-thirds of whom are 
women) currently have AD, and this number is expected to increase to nearly 
14 million by 2050 (Hebert et al., 2013). The number of people living with de­
mentia worldwide is estimated at 47.5 million and is projected to increase to 
75.6 million by 2030 and more than triple by 2050 (World Health Organization, 
2015). The estimated global cost of AD in 2015 was us$818 billion (McDade and 
Bateman, 2017 ), which according to the International Monetary Fund ( 2017) 
and the World Bank (2017), would rank as the 18th highest national gross do­
mestic product worldwide. 
Conversely, evidence has emerged in recent years suggesting that the in­
cidence and prevalence of AD and other less common dementias have been 
decreasing in some populations, perhaps for more than three decades (Langa 
et al., 2017; Satizabal et al., 2016). Improved risk factor management has been 
suggested as mitigating AD incidence and prevalence. However, a recent re­
port from the us Centers for Disease Control and Prevention, using state- and 
county-level death certificate data from the National Vital Statistics System 
for the period 1999-2014, demonstrates that the AD death rate increased by 
54°/o between 1999 and 2014 (Taylor et al., 2017). Between 2000-2014, the an­
nualized number of deaths from AD in the us increased by a remarkable 89% 
(Alzheimer's Association, 2017); while deaths from heart disease, stroke, and 
HIV decreased by 14°/o, 21%, and 54°/o, respectively (Shakoor et al., 2017). The 
reported increases in AD deaths and death rate are likely partly attributable to 
more careful reporting of the disease. 
AD is the sixth leading cause of death in the us, the fifth leading cause of 
death for persons 65 years old and older, and among the leading causes of dis­
ability and chronic poor health. Among the ten most common causes of death, 
AD is the only one with no effective approach for prevention, slowing disease 
progression, or cure. AD ranked 25th among diseases in the us, in terms of 
disability-adjusted life-years lost in 1990 and 12th in 2010, the largest change 
among the 30 leading diseases (us Burden of Disease Collaborators, 2013). It 
is not surprising that the public's fear of AD is escalating. In 2012, a Marist poll 
of 1,247 us adults found that AD was the most feared disease, chosen by 44% 
of participants compared to 33% for cancer, the second most feared disease 
(Help for Alzheimer's Families, 2012 ). 
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3 Animal Basic Science Research and Correlations 
Most basic science research of AD has used animals, predominantly mice 
(transgenic, inbred, and wild-type), but also rats and, to a lesser degree, other 
species, such as rabbits, dogs, and non-human primates. Numerous genetic 
mutations have been suggested to contribute to the pathological changes in 
the brains of AD patients, resulting in the selective breeding and research utili­
zation of many transgenic strains of mice and rats expressing those mutations 
(Cavanaugh, Pippin and Barnard, 2014; Do Carmo and Cuello, 2013; Jackson 
Laboratory, 2017; Webster et al., 2014). Because gene-disease links have been 
associated predominantly with autosomal dominant, early-onset familial 
AD ( accounting for fewer than 5% of cases), transgenic animal models have 
been based on early-onset disease; and the resultant data have been extrapo­
lated to relate to the much more common, late-onset sporadic AD. Research­
ers thus seek to recapitulate the genetic and pathological elements of human 
AD, thereby deriving mechanistic and therapeutic knowledge that is hoped to 
translate to the human condition. 
The business of breeding transgenic animal strains for AD research has 
flourished, and there are several commercial sources for these animals (Alz­
forum, 2017; Charles River, 2017; Jackson Laboratory, 2017; Taconic Biosciences, 
2017 ). Extensive lists of animal models for AD basic science research and drug 
development have been published, including information on specific genetic 
configurations and how these animals have been used ( Cavanaugh, Pippin and 
Barnard, 2014; Kumar et al., 2016; Neha et al., 2014; Puzzo et al., 2014). 
Because postmortem studies have identified specific brain pathologies 
among AD patients, most notably extracellular beta-amyloid (AB) plaques 
and intracellular neurofibrillary tangles (NFT), the great majority of basic sci­
ence research has used genetically modified animals to produce similar brain 
pathologies. AB plaques have been associated with localized inflammation, 
contributing to the neuronal and synaptic network damage believed to be 
related to AD symptoms and disease progression (Eikelenboom et al., 1989; 
Eikelenboom and Veerhuis, 1996; Rosenberg, 200s; Veerhuis, 2011). The ability 
to produce AB plaques and NFT in animal models has been available for more 
than three decades (Glenner and Wong, 1984; Kosik, Joachim and Selkoe, 1986; 
Wood et al., 1986). AB plaques are also formed, then often broken down and re­
moved in healthy human brains; but they persist and accumulate in AD brains. 
Further complicating the relationship between AB plaques and AD, studies 
have shown that 14°/0-21% of clinically diagnosed patients have zero or mini­
mal brain AB plaques on postmortem examination (Beach et al., 2012; Beekly 
et al., 2007; Serrano-Pozo et al., 2014). 
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Tau proteins serve an essential role in the structure and function of microtu­
bules that regulate intracellular transport of important nutrients. NFT consist 
of hyperphosphorylated tau proteins, resulting in characteristic fibrillar struc­
tures and microtubule dysfunction, contributing to neuronal destruction as 
well as disruption of axonal growth and plasticity (Kosik, Joachim and Selkoe, 
1986; Wood et al., 1986). Both extracellular AB and intracellular NFT are be­
lieved to extend damage to the brain's connecting network of dendrites and 
axons, thereby disrupting intercellular communication and contributing to 
loss of neurons and neuronal networks. The postulated causative role for AB 
and NFT in clinical AD is further confounded by findings that both pathologies 
have been identified in the brains of patients with frontotemporal dementia, 
Parkinson disease, Huntington disease, Down syndrome, and amyotrophic 
lateral sclerosis, as well as in normal brains ( Cavanaugh, Pippin and Barnard, 
2014; Masters et al., 1985; Ross and Poirier, 2004). 
Mutations in genes encoding amyloid precursor protein (APP), as well as 
the gamma secretase catalytic proteins presenilin 1 (PSEN1) and presenilin 2 
(PSEN2), have also been linked to familial AD and have been employed in the 
study of the disease in animals (Borchelt, et al., 1997; Chartier-Harlin et al., 1991; 
Goate et al., 1991; Levy-Lehad et al., 199s; Mullan et al., 1992 ). Inheritance of the 
apolipoprotein E type 4 allele (ApoE4) has been linked to an increased risk for 
late-onset AD, though the gene-disease link is weakened by the fact that the 
ApoE4 allele is neither necessary nor sufficient to predict AD ( Corder et al., 1993; 
Rossor etal., 1996; Sadigh-Eteghadet al., 2012; Strittmatter et al., 1993).Numerous 
transgenic or double-transgenic animal models have induced and accelerated 
the development of AB plaques and have produced associated brain inflam­
mation with cognitive and behavioral pathologies. These models have not pro­
duced NFT, but NFT have been produced in conjunction with cognitive deficits 
by animal models expressing mutated tau protein. A triple transgenic mouse 
model expressing mutated human AB precursor protein, PSEN1, and tau protein 
was developed to generate both AB plaques and NFT; this model also produced 
associated gliosis, synaptic pathology, and impaired memory ( Oddo et al., 2003). 
The senescence-accelerated mouse prone 8 (sAMP8) strain with a mean 
lifespan of 9.7 months is considered by researchers to be more suitable to 
investigate late-onset AD (Pallas, 2012). SAMP8 mice exhibit dendritic spine 
loss, spongiosis, gliosis, and forebrain cholinergic deficits, while develop­
ing A� deposits and aberrant hyperphosphorylated tau-like NFTs ( Cheng, 
Zhou and Zhang, 2014). Despite extensive characterization of SAMP and the 
SAMP8-APP /PSEN1 mouse model (i.e., double transgenic for amyloid pre­
cursor protein and PSEN1 in the senescence-accelerated background of 
SAMP8) (Lok et al., 2013; Porquet et al., 2015), the genes responsible for senes­
cence and the observed pathological traits are largely unknown. Moreover, 
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SAMP8-APP /PSI mice exhibit significant differences in A� plaque formation 
and cognitive abnormalities when compared with human AD (Porquet et al., 
2015). 
Further information, regarding the specific animal models, their phenotyp­
ic results, and their contributions to the knowledge base for animal surrogates 
of human AD and some important biological and outcome differences, is avail­
able ( e.g., Cavanaugh, Pippin and Barnard, 2014; Esquerda-Canals et al., 2017; 
Geerts, 2009; Kumar et al., 2016). 
Many of the animal experiments have been successful in determining the 
pathogenesis and progression of simulated AD-like disorders at the molecular, 
cellular, and behavioral levels for the transgenic species studied. Some topics, 
such as steps in amyloid and tau pathways, have prospered from transgenic 
animal studies. However, though various transgenic models develop specif­
ic phenotypical aspects of AD- not only AB plaques and NFT, but also re­
lated gliosis, synaptic alterations, neurodegeneration, behavioral changes, 
and memory deficit-no individual animal model or combination of mod­
els replicates the clinicopathological complexity of human Alzheimer or 
translates to improved outcomes for Alzheimer patients (Dodart et al., 2002; 
Duyckaerts, Potier and Delatour, 2008). 
What are the correlations between the extensive animal-derived knowledge 
and the etiology, risk factors, clinical course, pathophysiology, treatments, and 
outcomes of AD, and what is the payoff expected from basic science research? 
It is now well understood that, despite the plethora of Alzheimer animal 
models in use, the interspecies translation is poor for genetic, physiological, 
and technical reasons (Neha et al., 2014). No matter how close two species, 
or even two strains within a species, may be genetically, there are immutable 
differences in gene function, gene expression, protein production, and phe­
notypic or physiological results that render translation unpredictable and un­
reliable. Description and explanation of many animal-human discrepancies 
specific to AD are available ( see Cavanaugh, Pippin and Barnard, 2014; Langley, 
2014). The demonstrated inability to modify animal models to improve trans­
lation provides further evidence that only a shift to human-derived and, thus 
human-relevant, research methods can improve the applicability of basic sci­
ence research to human AD. 
4 Animal Drug Development Research and Outcomes 
The translational goal of basic science research for medical diseases is to 
provide the knowledge required to predict, prevent, identify, treat, and hope­
fully cure these diseases. As such, the success of this approach for AD can be 
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measured, in substantial part, by assessing the role of animal research in phar­
maceutical development. Over the past three decades, basic and applied sci­
ence research have identified mechanisms leading to the discovery of drug 
targets and the development of drugs customized for those targets. An exten­
sive review of these targets, drugs, and clinical trial results is beyond the scope 
of this chapter but may be found elsewhere ( see Berk and Sabbagh, 2013; Cava­
naugh, Pippin and Barnard, 2014; Langley, 2014; Schneider et al., 2014). 
Though the current discussion is limited to AD, context is also important 
in fairly assessing the success of preclinical animal research for drug develop­
ment. For the past eight decades, preclinical testing methods for the safety and 
efficacy of drugs have relied heavily on the use of animals, not least because 
this has been the default approach of the us Food and Drug Administra­
tion (FDA) and regulatory agencies in most other regions of the world. This 
animal-testing paradigm has never been subjected to a systematic validation 
of translation to human medicine or consistency among or within non-human 
species and different laboratories. Former FDA pharmacology and toxicology 
reviewer, Anita O'Connor, confirmed this situation in 1998, stating that: "Most 
of the animal tests we accept have never been validated. They evolved over the 
past 20 years, and the FDA is comfortable with them." Similarly, in the United 
Kingdom, Parliamentary Under-Secretary of State, Caroline Flint stated, in 
2004, that: "The Home Office has not commissioned or evaluated any formal 
research on the efficacy of animal experiments" (UK Parliament, 2004). This 
situation persists not only in these two nations. 
As far back as 2003, the FDA reported a clinical trial failure rate of 92% for 
drugs deemed safe and effective based on preclinical animal studies, a marked 
increase from the already high 86% attrition rate in 1985, despite purported 
advances in preclinical drug testing (FDA, 2004; Mitka, 2006; Singh and Hen­
ske, 2003). The most recent phase-specific data for drugs tested safe and ef­
fective in preclinical animal studies identified clinical trial attrition rates of 
56% for Phase I ( designed to assess drug safety and estimate dosing); 82% for 
Phase I I ( designed to assess proof of concept); and 50% for Phase I I I ( designed 
to assess safety and effectiveness for humans) ( Arrowsmith, 20na; Arrowsmith, 
2onb; Lovell-Badge, 2013)-a cumulative 96% failure rate. When drug with­
drawals, duplicative "me too" drugs, and low patient response rates are includ­
ed, only about one in one hundred drugs that are tested successfully in animals 
becomes a unique, effective, and safe medication; and then it is very likely to 
be effective for only a minority of patients and often marginally so. This is cer­
tainly the case with the four drugs licensed to treat AD. 
There could hardly be stronger evidence that animal use for drug testing 
is very unreliable and poorly contributes to drug efficacy or safety in the real 
world. Added to this serious false-positive problem are the missed opportunities 
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for useful drugs, due to false-negative animal testing and adverse effects that 
would not translate to humans. The cause-effect relationship between animal 
testing and clinical trial results was succinctly stated by Stanford's Joseph Gar­
ner ( Gamer, 2014, p. 440 ): 
The logic tying failures in clinical trials to basic research in animals is 
seductively straightforward. Every drug entering human trials, by defini­
tion, "worked" in an animal model in terms of both safety and efficacy, 
and efficacy is the primary reason drugs fail in human trials. Thus, the 
primary reason for these failures can be traced back directly to false 
positives in animal models committing the pipeline to develop a drug 
that will ultimately fail. Straightforward data can be used to make this 
case. For instance, as reviewed by Zahs and Ashe ( 2010 ), over 200 different 
interventions have been reported to be effective in the APP mouse model 
of Alzheimer's disease, yet none has proven effective in human trials. 
Animal research addressing drug development for AD is even worse than the 
overall pattern described above. Despite the 2,204 AD clinical trials (including 
1,329 completed, terminated, suspended, and withdrawn drug studies) listed at 
ClinicalTrials.com on July 24, 2017, only four drugs are currently FDA-approved 
for treatment of the disease alone or in combination (Table 20.1). Three of 
these are acetylcholinesterase inhibitors (AChEI), which inhibit the depletion 
of the crucial neurotransmitter acetylcholine in AD. The fourth drug is a N­
methyl-D-aspartate (NMDA) receptor antagonist that inhibits the destructive 
excitatory action of glutamate at the cellular level. 
It is perhaps a measure of the dearth of therapies to address AD that the 
FDA has approved even these few drugs, which only scratch the surface of AD 
therapy. The drugs produce very small changes, of dubious clinical relevance, 
on cognitive and behavioral measurement scales (Delrieu et al., 2011); they typ­
ically have mild impact on symptoms in only a minority of patients, have no 
effect on disease progression or mortality, often lose any effectiveness within 
several months, and may produce serious adverse effects. 
Despite the low bar for FDA approval of AD drugs, the pharmaceuti­
cal industry trade group, Pharmaceutical Research and Manufacturers of 
America (PhRMA ), reported that between 1998-2014, 123 drugs failed in AD 
clinical trials (2015), further supporting the organization's comments in its 
2012 report: "The limited utility of current models of the human disease is a 
huge barrier in preclinical testing of drug candidates [ .... ] Unfortunately, these 
medical treatments do not always work, they cannot cure the disease or stop 
its progression, and when they work their efficacy often wears off over time" 
(PhRMA, 2012 ). 
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TABLE 20 . 1  FDA-approved drugs for  Alzheimer disease (2019) 
Drug name Brand name Category FDA Approved Approved 
approval disease stages generic 
Donepezil Aricept AChEJa 1 996 All stages Yes 
Rivastigmine Exelon AChEI 2000 Mild-moderate Yes 
Moderate-severeb 
Galantamine Razadyne AChEI 200 1 Mild-moderate Yes 
Memantine Namenda NMDARIC 2003 Moderate-severe Yes 
Donepezil + Namzaric AChEI + 2 0 1 4  Moderate-severe Yes 
memantine NMDARI 
a Acetylcholinesterase inhibitor 
b Patch is approved for moderate-severe 
c N-methyl-D-aspartate receptor inhibitor. 
The AChEI tacrine was approved for mild-moderate AD in 1 993 and withdrawn in 2 0 1 3  due to 
severe toxicities 
Cummings, Morstorf and Zhong ( 2014) reported on all registered AD drug 
trials for the period between 2002-2012, using NIH's ClinicalTrials.gov data­
base to extract drug and trial data. They found that during this period, 244 
candidate AD drugs were tested in 413 clinical drug trials. There was a 72% 
attrition rate for Phase I trials, which reached 92% when Phase I I  trials were 
added. Only one drug succeeded in Phase I I I  to achieve FDA approval (me­
mantine in 2003). The failure rate was 99.6% (243 of 244 the drugs tested). An 
analysis of AD clinical drug trials reported from January 11 2004 ( after meman­
tine approval) through to July 19, 2017, reveals 1,273 completed or closed trials 
and no approved drugs ( ClinicalTrials.gov, n.d. ). 
PhRMA reported 77 AD drugs in clinical trials in 20161 21 of which were in 
Phase I I I  studies (PhRMA, 2016). By May 2017, nine of these drugs had already 
failed at least one late-stage trial, none had a successful outcome, and numer­
ous others no longer had trials registered on ClinicalTrials.gov. In January 
2016, ClinicalTrials.gov listed 93 agents in 115 open AD trials: 24 agents in 36 
Phase I I I  trials, 45 agents in 52 Phase I I  trials, and 24 agents in 27 Phase I trials 
(Cummings, Morstorf and Lee, 2016). In July 2017, none of these had achieved 
a successful outcome. Data from the July 2017 Alzheimer's Association 
International Conference reported 58 Phase I I  and 32 Phase I I I  AD drugs in 
development, including 8 Phase I I  and 27 Phase I I I  drugs expected to launch 
in the next five years (Henriques, 2017; Us Against Alzheimer's, 2017). 
Table 20.2 displays notable drugs that have failed late-stage clinical trials in 
the past six years. Some drugs have failed several clinical trials and some have 
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continued to be evaluated in additional late-stage clinical trials. Among drug 
candidates currently in Phase 1 1 1  trials are AE antibodies aducanumab (Bio­
gen) and crenezumab (Hoffmann-La Roche); BACEi inhibitors elenbecestat 
(Biogen) and JNJ-54861911 (Janssen); 5-HT6 antagonist SUVN-502 (Suven Life 
Sciences); and NMDA receptor antagonist AVP-786 (Avanir). 
Cumulatively, Cummings et al.'s (2014) results from 2002-2012 data and 
results for 2013-2018, shown in Table 20.2, demonstrate that at least 265 
AD drugs have failed in clinical trials in the past 15 years. The race between 
translatable research and burgeoning disease is being lost, with no clear path 
TABLE 2 0 . 2  Notable Alzheimer drug failures from 2013-2018 
Failed drug Category Sponsor Most recent Reason for failure 
failed trial 
LY 288672 1 BACE 1 inhibitor Lilly 201 3 Toxicity 
Intravenous lg Immune modulator Baxter, Intl. 20 13  Ineffective 
Begacestat y secretase inhibitor Bristol-Myers 20 13  Ineffective 
Squibb 
Bapineuzumab AE antibody Pfizer 2014  Ineffective 
Affitope AD02 AE vaccine AFFiRiS AG 2014  Ineffective 
PF04447943 PDEgA inhibitor Pfizer 2014  Ineffective 
Gantenerumab AB antibody Hoffmann-La 2014  Ineffective 
Roche 201 5 Toxicity 
BI 1181181 BACEI/2 inhibitor Boehringer 201 5 
Ingelheim 
ffi-3 fatty acid Dietary supplement University 201 5 Ineffective 
Hospital, Toulouse, 
France 
Sembragiline MAO-B inhibitor Roche 201 5 Ineffective 
Encenicline a7 NAR agonist FORUM 201 5 Toxicity (FDA 
halted) 
Masitinib Tyrosine kinase AB Science 201 5 Ineffective 
inhibitor 
AB vaccine 
CAD 106 Novartis 20 16  Ineffective 
Idalopirdine 5-HT6 antagonist Lundbeck & 2016  Ineffective 
Otsuka 
PF052 12377  5-HT6 antagonist Pfizer 20 16  Ineffective 
Bexarotene Anti-neoplastic Cleveland Clinic 20 16  Ineffective 
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TABLE 20 . 2  Notable Alzheimer drug failures from 2013-2018 (cont. ) 
Failed drug Category Sponsor Most recent Reason for failure 
failed trial 
LMTX Tau aggregation TauRx 2016  Ineffective 
inhibitor 
Bryostatin PKC modulator Neurotrope 2017  Ineffective 
AC-1204 Ketosis inducer Accera 2017 Ineffective 
Intepirdine 5-HT6 antagonist Axovant Sciences 2017 Ineffective 
BAN2401 AB antibody Biogen/Eisai 2017 Ineffective 
Solanezumab AB antibody Lilly 2018 Ineffective 
Pioglitazone antiglycemic Takeda/Zinfandel 2018 Ineffective 
BI  409306 PDEgA inhibitor Boehringer 2018 Ineffective 
Ingelheim 
Verubecestat BACEI inhibitor Merck 2018 Ineffective 
Azeliragon RAGE inhibitor vTv 2018 Ineffective 
Pimavanserin 5-HT2A antagonist Acadia 2018 Ineffective 
Atabecestat BACEI inhibitor Johnson & Johnson 2018 Toxicity 
Lanabecestat BACEI inhibitor Lilly 2018 Ineffective 
Elenbecestat BACEI inhibitor Biogen/Eisai 2018 Ineffective 
BACE1=beta-site amyloid precursor protein-cleaving enzyme 1; lg=immunoglobulin; 
RAGE=receptor for advanced glycation endproducts; PDEgA=phosphodiesterase gA; 
MAO-B= monoamine oxidase B; a7 NAR=a7 nicotinic acetylcholine receptor; 5-HT6=5-
hydroxytryptamine (serotonin) type 6 receptor; PKC=protein kinase C; 5-HT2A=s­
hydroxytryptamine (serotonin) type 2A receptor. 
to improvement other than the replacement of the failed animal research par­
adigm by a commitment to human-relevant research methods. 
5 Whither the Amyloid Cascade Hypothesis? 
The amyloid cascade hypothesis, in its initial description (Hardy and Allsop, 
1991; Hardy and Higgins, 1992) and in its reappraisal (Hardy, 2006; Hardy and 
Selkoe, 2002 ), has been foundational for AD preclinical and clinical research for 
a quarter of a century. Early and widespread acceptance of the hypothesis has 
impacted research gatekeepers, such as funding agencies, journal editors, peer 
reviewers, and pharmaceutical companies. The amyloid cascade hypothesis, 
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derived from human autopsy studies, identifying the presence and presumed 
causative roles for AE plaques and tau proteins, proposes that sequential enzy­
matic cleavage of mutated APP by secretase enzymes results in deposition of 
soluble AE protein oligomers that coalesce into plaques, and that downstream 
events include tau protein and NFT formation and cell death. The specifics of 
inflammation and destruction of neuronal networks were identified with fur­
ther investigation. This entire process is termed, neurodegeneration. 
In the pursuit of AD research, abundant information has been obtained 
casting doubt on the amyloid cascade hypothesis. Paramount among con­
trary information is the finding that a meaningful percentage of young adult 
(Baker-Nigh et al., 2015) and older persons (Armstrong et al., 1996; Esparza 
et al., 2013; Haroutunian et al., 2008; Mansell et al., 2013; Price et al., 2009 ), 
without dementia, have substantial AB plaque deposition demonstrated in 
brain imaging and postmortem studies. In one large review, amyloid bio­
markers increased with age and were present in 10%-44°/o of cognitively 
normal participants aged 50-90 years (Jansen, et al., 2015). Lon Schneider of 
the University of Southern California, Keck School of Medicine, stated that: 
"There are people who die with a head full of amyloid and have no cogni­
tive impairment whatsoever" (Mullin, 2017 ). Conversely, AB plaques may be 
absent or minimally present in clinically diagnosed AD patients (Mansell 
et al., 2015; Morris, Clark and Vissel, 2014; Terry et al., 1991). A recent report 
demonstrates that tau oligomers, produced subsequent to AE deposition, are 
also present in the sera of aged normal controls as well as AD patients (Ko­
larova et al., 2017). It has been reported that some degree of tau pathology is 
ubiquitous in postmortem human brains (Braak and Braak, 1997; Braak and 
Del Tredici, 2011). 
Since some drugs have successfully removed brain AE plaque without pro­
ducing improvement in cognition and other symptoms and without improv­
ing clinical course or mortality, it has been proposed that AE plaques may not 
be causative for AD. Tau pathology not only is triggered by AB plaques but also 
appears to progress unabated even after the removal of AE plaques, suggesting 
that therapies targeting AE are unlikely to succeed in controlling AD (Hampel 
et al., 2010; Wang et al., 2016). Some recent basic science and drug development 
research has focused on a possible AD causative role for tau proteins rather than 
AB plaques, but the only completed tau-targeting Phase III drug trial ( a tau 
protein aggregation inhibitor known as LMTX, LMTM, or TRxo237) failed to show 
benefits (Alzforum, 2016a). The true AD target may be the synaptic and neu­
ronal network destruction that is the common final pathway to dementia. An 
alternative interpretation is that the timing of AB-targeted therapies may be 
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key: Once AE plaque has formed, it may be too late to reverse the pathological 
consequences. 
AD has appropriately been described as late-life phenotypes, beginning as 
midlife pathologies with a two-decade or more latency period. There is now 
a corresponding move towards identifying and validating biomarkers to aid 
in detecting AD in its earliest stages, or even before symptoms appear, so that 
the neuronal network damage may be prevented rather than treated (Dono­
hue et al., 2017; Schneider et al., 2014). Foremost among these approaches 
may be prevention trials enrolling asymptomatic persons, with character­
istic neuroimaging pathology or with specific cerebrospinal fluid biomark­
ers (Donohue et al., 2017; Jansen et al., 2015; Olsson et al., 2016; Ramachan­
dran, 2016), and targeting subsequent cognitive loss and the development of 
M C I  or AD . 
Earlier intervention is a logical approach derived from the failure of later 
clinical intervention, but its value is debatable for at least three reasons. First, 
the biomarkers indicating risk for AD are not yet sufficiently accurate to ex­
clude persons who would never develop AD or even M C I  from clinical trials. 
Second, fewer than half of persons with M c  I will progress to AD, making even 
this indicator of limited utility and suggesting that earlier biomarkers may be 
fraught with low specificity and positive predictive value (Mitchell and Shiri­
Feshki, 2009; Richard and Brayne, 2014; Roberts et al., 2014a; Ward et al., 2013). 
Third, this approach does not directly address the failure of animal research to 
identify disease-modifying therapies, though it is postulated that some failed 
therapies may be effective if applied earlier. 
So, the fate of the amyloid cascade hypothesis remains unknown but ap­
pears tenuous; and its demise would seriously compromise decades of basic 
science, clinical, and pharmaceutical efforts. Outcomes to date have not con­
firmed, and generally do not support, the amyloid cascade hypothesis; and 
if current and pending early-stage and presymptomatic AB-targeted studies 
fail to impact outcomes, it must be presumed to be incorrect. It is axiomatic 
that the first step in understanding, characterizing, and addressing disease 
is to determine the cause(s). We have not demonstrably done this for AD, 
arguably because basic science research, predominantly using transgenic 
animals, has been unable to accomplish the task despite more than three 
decades of effort. 
6 The Expanding Role of Lifestyle Factors for AD Prevention 
Concomitant with the emphasis on earlier detection and preventive mea­
sures for AD, there is a need to identify factors that are predictive of, 
Kathrin Herrmann and Kimberley Jayne - 978-90-04-39119-2 
Downloaded from Brill.com11 /11 /2019 09:57:0BPM 
via free access 
ANIMAL RESEARCH FOR ALZHEIMER DISEASE 493 
contributory to, or protective for the development of cognitive impairment 
and AD. In particular, modifiable lifestyle factors associated with risk for 
cognitive impairment and AD offer a particularly appealing approach to 
prevention-lifestyle modifications without adding heretofore failed drug 
treatments. 
Blood pressure-pressure variability rather than absolute systolic, diastolic, 
or mean blood pressure-has been associated with risk for subsequent cogni­
tive decline and AD in a unique manner. The same pattern of greater cognitive 
decline with greater blood pressure variability has been established for office 
(Alperovitch et al., 2014; Sabayan et al., 2013); ambulatory (McDonald et al., 
2017); and home (Matsumoto et al., 2014; Oishi et al., 2017) blood pressure mea­
surements and for day-to-day or month-to-month variability. Though blood 
pressure variability has also been shown to correlate with cardiovascular event 
risk and target organ damage (Kikuya et al., 2008; Rothwell et al., 2010 ); it is un­
known whether there are shared mechanisms with cognitive decline, and it is 
also unknown whether specific blood pressure control efforts impact the cog­
nitive risk (Palatini, 2014). Observational studies of hypertension and cognitive 
risk have been heterogeneous, but the evidence is strongest for risk correlation 
between mid-life hypertension and late-life AD and all cause dementia (Ken­
nelly, Lawlor and Kenny, 2009a; Kennelly, Lawlor and Kenny, 2009b; Purnell et 
al., 2009; Qiu, Winblad and Fratiglioni, 2005), with an estimated relative risk of 
1.6 (Barnes and Yaffe, 2011). 
Regular exercise is a topic of great interest for potential reduction of the 
risk for cognitive decline and AD. A prospective study of 200 persons with 
mild dementia evaluated cognitive outcomes of a group receiving 16 weeks 
of supervised exercise and a non-exercise control group. No differences were 
seen in objective measures of cognition, quality of life, or ability to perform 
activities of daily living (Hoffman et al., 2016). This outcome was confirmed 
in a Swedish study of 186 persons with dementia who participated in an in­
tensive four-month exercise program (Toots et al., 2017). A Western Australia 
prospective trial evaluated exercise effect on cognition among 138 at-risk older 
adults, randomized to either 24 weeks of supervised physical activity or no ex­
ercise. This methodologically problematic study showed minimal and dubi­
ous improved cognitive measures over 18 months (Lautenschlager et al., 2008). 
In a secondary analysis of the randomized prospective LIFE trial, a 24-month 
physical activity intervention involving 1,635 sedentary older adults, no exer­
cise-related improvements were seen in global or domain-specific cognitive 
function (Sink et al., 2015). 
In contrast, a 2009 meta-analysis of 16 studies including 163,797 nonde­
mented participants showed an approximate 45°/o reduced risk for AD and 
28% reduction in all-cause dementia, between the highest and lowest physical 
Kathrin Herrmann and Kimberley Jayne - 978-90-04-39119-2 
Downloaded from Brill.com11 /11 /2019 09:57:0BPM 
via free access 
494 PIPPIN, CAVANAUGH AND PISTOLLATO 
activity groups, with a relative risk among inactives of 1.82 for AD (Hamer and 
Chida, 2009 ). Another systematic review reported that physical inactivity was 
linked to an increased risk for cognitive impairment in 20 of 24 included stud­
ies (Rolland, Abellan van Kan and Vellas, 2008). A 2010 meta-analysis of 15 pro­
spective studies, including 33,816 nondemented subjects, who were followed 
for 1 to 12 years, showed a decreased risk for subsequent cognitive decline at 
all exercise levels (Sofi et al., 2010 ). These meta-analysis findings were com­
promised by conflicting results and methodological heterogeneity among the 
studies reviewed. A secondary analysis of a 30-year questionnaire-based study 
of midlife exercise found no relationship to subsequent cognitive impairment 
or dementia ( Gross et al., 2017 ). 
The majority of studies evaluating exercise or uncharacterized physical 
activity as predictors of subsequent cognitive impairment, AD, or all-cause 
dementia are observational cohort studies, variably compromised by method­
ological limitations. These limitations include poorly characterized or unsu­
pervised exercise, inconsistent exercise and activity patterns, self-reporting by 
subjects, questionnaire-based data collection (subject to recall bias), research­
er bias, variable influence of the observers on participant performance, and 
short interventional and observational periods, among other disadvantages. 
Cumulative findings to date show no significant evidence for exercise benefit 
regarding progression among persons with dementia, and conflicting evidence 
for benefit regarding future development of cognitive decline, AD, or all-cause 
dementia. 
The relationship of diet to risk for cognitive decline and AD or uncharacter­
ized dementia is a revealing area of investigation. Studies of specific dietary 
supplements have predominantly failed to show decreased risks for prevalent 
or incident cognitive decline and dementia, excluding replacement therapy 
for severe nutritional deficiencies, such as vitamin B12 and niacin. Dietary sup­
plement animal research supports beneficial effects for vitamins C, D, and E 
(Anastasiou, Yannakoulia and Scarmeas, 2014; Guerrero et al., 1999; Joseph et 
al., 1998; Socci, Crandall and Arendash, 1995; Yamada et al., 1999 ). Human stud­
ies of dietary vitamin intake have shown inconsistent results. Prospective ob­
servational studies in Chicago (Morris et al., 2002) and Rotterdam (Engelhart 
et al., 2002) showed lower AD risk with greater dietary vitamin E intake, while 
a similar study in New York showed no association (Luchsinger et al., 2003). 
The Rotterdam study showed lower AD risk with greater vitamin C intake, but 
the other two studies did not. The Chicago study also found a worrisome posi­
tive correlation between vitamin C intake and the risks for hypertension and 
stroke. None of the three studies showed benefit from vitamin C or vitamin E 
supplements. 
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In a 2014 study of elderly hospitalized patients, blood levels of 25-hydroxy 
vitamin D did not discriminate among cognitively normal (200 ); M CI (46); and 
demented (182) patients, nor did the levels predict conversion to dementia 
(Graf et al., 2014). Conversely, another observational study showed a relative 
risk for incident AD of 1.69 for deficient and 2.22 for severely deficient vitamin 
D levels among 1,658 healthy ambulatory adults (Littlejohns et al., 2014). Over­
all, human vitamin D study outcomes have been heterogeneous, but the high­
est quality evidence ( clinical trials) does not support vitamin D-related benefit 
(Anastasiou, Yannakoulia and Scarmeas, 2014). 
Dietary saturated fat and trans fat intake have been associated with higher 
AD risks in human studies (Kalmijn et al., 1997; Luchsinger et al., 2002; Mor­
ris et al., 2003), though this correlation disappeared during follow-up in one 
study (Kalmijn et al., 1997 ). A more recent systematic review revealed mixed 
evidence among four observational studies of saturated fat and trans fat in­
take and M CI or dementia (Barnard, Bunner and Agarwal, 2014). A study of 444 
Finnish men linked elevated midlife blood cholesterol with increased subse­
quent AD risk (Notkola et al., 1998). Observational studies have reported lower 
AD risk with statin therapy (lick et al., 2000; Wolozin et al., 2000 ); but a 2016 
Cochrane review found no benefit on five cognitive tests in two randomized 
placebo-controlled trials of statins, including 261340 participants (McGuin­
ness, et al., 2016). Diets consisting substantially of meat, dairy, processed and 
fatty foods, snack foods ( often high in trans fats), and high caloric content con­
tribute to known AD risk factors as well as other health risks. 
The pattern of accelerated AD and all-cause dementia after adoption of the 
American-style diet is widely evident, including in Japan (Grant, 2014), China 
(Chan et al., 2013), rural India (Chandra, et al., 1998), eight developing nations 
(Grant, 2014), and among participants in the Adventist Health Study (Giem, 
Beeson and Fraser, 1993). A recent comprehensive review of dietary data and 
cognitive risks from 2014-2016 presented updated data regarding seafood 
intake and lines of evidence against cognitive protection, despite the pur­
ported favorable effects of the omega-3 fatty acids, eicosapentaenoic acid, and 
docosahexaenoic acid (Solfrizzi et al., 2017). 
Type 2 diabetes mellitus (T2DM) is an AD risk factor, resulting predomi­
nantly from the combined and cumulative effects of poor diet, sedentary 
lifestyle, and obesity. T2DM and AD are known to share pathologies, such 
as cerebrovascular disease, brain atrophy and diminished brain volume, im­
paired brain glucose metabolism, and CNS insulin resistance (Asih et al., 2017; 
Bharadwaj et al., 2017; Sutherland et al., 2017); and both disorders have been 
linked to tau pathology and neurodegeneration (Sutherland et al., 2017). At the 
clinical level, T2DM and AD both increase in incidence with age; and risks for 
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both have been shown for sedentary lifestyle, hypertension, poor diet, obesity, 
dyslipidemia, and smoking. Overlapping features, including the role of insulin 
resistance in the brain, have resulted in the designation of AD as "type 3 diabe­
tes" (De La Monte and Wands, 2008). 
Observational cohort studies, systematic reviews, and meta-analyses have 
predominantly identified T2DM in cognitively normal persons as a risk fac­
tor for M C I ,  AD , and all-cause dementia (Barnes and Yaffe, 2011; Biessels 
et al., 2006; Biessels et al., 2014; Cheng et al., 2012; Cukierman, Gerstein and 
Williamson, 2005; Exalto et al., 2012; Gudala et al., 2013; Kopf and Frolich, 2009; 
Lu, Lin and Kuo, 2009; Roberts, et al., 2014b; Yaffe, et al., 2012; Zhang et al., 2017 ), 
though some of these studies have methodological flaws and unaccounted bias 
(Sutherland et al., 2017 ). This correlation was not confirmed for the progression 
of cognitive decline among AD patients (Li et al., 2017). Several investigators 
have estimated the relative risk for AD from T2D M as 1.5 ( Chatterjee et al., 2016; 
Cheng et al., 2012; Gudala et al., 2013), including recent population-based stud­
ies of more than 2.3 million (Chatterjee, et al., 2016) and more than 1.7 million 
persons (Zhang et al., 2017). A combined systematic review and meta-analysis 
of eight studies of T2DM and AD risk reported that seven studies found a posi­
tive correlation, but only two reached statistical significance, and overall rela­
tive risk was 1-4- (Lu, Lin and Kuo, 2009 ). 
The risk for development of M c  I ,  AD, and all-cause dementia increases with 
T2DM duration (Asih et al., 2017; Bruce et al., 2014). Dementia risk appears to 
be proportional to diabetes severity (Yaffe, et al., 2012 ), to occur at a younger 
age when T2DM is present (Zilkens et al., 2013), and to display shorter survival 
when combined with T2DM (Helzner et al., 2008; Zilkens et al., 2013). The rap­
idly increasing worldwide prevalence of T2DM, thus, suggests not only more 
prevalent AD, but also younger onset and shortened survival for AD patients. 
Conversely, improved T2DM prevention would be expected to have a benefi­
cial effect on AD prevalence, onset, and mortality. 
Based on the preceding and similar findings, certain recommendations can 
be made to minimize modifiable risks for cognitive decline and AD. These rec­
ommendations are built on the preponderance of evidence from human stud­
ies and the overall beneficial effects for cardiovascular disease, T2DM, obe­
sity, hypertension, and other AD risk factors as well as for the hard endpoints 
of cognitive decline and dementia. Elements of the lifestyle prescription in­
clude, regular exercise or other physical activities; adoption of heart-healthy 
diets, such as the Mediterranean diet and other plant-based diets emphasizing 
fruits, vegetables, whole grains, and legumes (with consideration for exclud­
ing seafood consumption due to cholesterol content and uncertain benefit); 
preference for food sources rather than supplement sources of potentially 
protective dietary components; maintenance of normal body weight, blood 
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pressure, blood glucose and lipids; and other factors not discussed here, such 
as not smoking and attainment of at least a high school level of education. As 
a bonus, and in contrast to drug therapies, the side effects of this prescription 
are beneficial. 
7 Brief Overview of Research Funding 
During the first decade of the twenty-first century, AD research funding from 
NIH was strikingly low, compared to other widespread, lethal, and costly dis­
eases. Passage of the us National Alzheimer's Project Act (NAPA) by Congress 
in January 2011, focused greater emphasis on AD research, and federal funding 
increased slowly until the 2016 and 2017 fiscal years showed large increases. 
In 2012, NIH research funding for AD and AD-related dementias was half a 
billion dollars, compared to us$1.3 billion for heart disease, us$3.1 billion for 
HIV/AIDS, and us$5.6 billion for cancers. AD research funding did not exceed 
us$6oo million until 2015, but it received a 60% increase in 2016 and a 40% 
increase in 2017 (Alzforum, 2016b; Moore, 2017; NIH, 2016). Projected NIH AD 
research funding for 2017 is nearly us$1.4 billion, almost triple the funding of 
the past five years, while funding for heart disease, HIV/AIDS, and cancers has 
remained unchanged. 
While this is very good news for AD research, the devil is in the details. NIH 
funding in this area has been heavily weighted towards animal research for at 
least the past decade, supporting three times as many animal research proto­
cols as human-specific protocols, and spending more than twice as many tax 
dollars for animal research (Figure 20.1). Total NIH expenditures for AD and 
AD-related dementia research since 2011 is more than us$5 billion, with no 
clinical return on this investment. If this pattern of dependence on animal re­
search is unchanged, genetic principles, interspecies differences, and history 
tell us that the AD animal research paradigm will continue to fail in producing 
advances in AD prevention and treatment, regardless of how much money is 
directed towards that goal. 
Some private funding sources, which collectively distribute tens of mil­
lions of dollars annually for AD research, have shown a broader perspective 
regarding the directions for AD research. For example, in 2016 the Alzheim­
er's Association partnered with philanthropist Michaela Hoag to announce 
its Part the Cloud Challenge and grants totalling us$7 million to fund clinical 
trials investigating brain inflammation in AD (Alzheimer's Association, 2016). 
The Alzheimer's Drug Discovery Foundation (2017) funds many non-amyloid, 
non-tau research approaches. The Paul G. Allen Family Foundation's us$7 mil­
lion award in 2015 sought innovative AD research approaches, emphasizing the 
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FIGURE 20 . 1  N IH  funding for  Alzheimer disease research. 
Bar graphs report the absolute numbers of Alzheimer's-related projects 
focused on the use of animal models (black bars) versus projects accounting 
only for human-relevant models/methods (white bars) . (A) and (B) present 
relative funding provided by the N IH  from 2007 to 2017. (Updated from 
Pistollato et al., 2016) 
human disease, and the Microsoft cofounder stipulated that at least one mem­
ber of each of the five recipient research teams must not be an AD researcher 
(Begley, 2016; Paul G. Allen Philanthropies, 2015) .  Similarly, the Darrell K. Royal 
Research ( D KR) Fund for Alzheimer's Disease ( 2016) "is interested in novel, 
innovative and cutting-edge approaches to Alzheimer's disease, dementia, 
Traumatic Brain Injury, and related disorders. Additionally, the DKR Fund 
is particularly interested in non-amyloid and non-tau approaches that may 
not receive funding through traditional mechanisms. Studies that pilot novel 
mechanisms and novel therapeutic interventions are particularly encouraged." 
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(Underline in original.) It is through innovative and nontraditional research 
design, specifically human-relevant research, that the inability to translate ba­
sic science discoveries to AD prevention, treatment, and successful drug devel­
opment may be overcome. 
8 Conclusions: The Process and the Ethics 
Perhaps as starkly as for any other disease, AD research ethics must address 
both animal use and human outcomes. This is because the animals suffer cap­
tive breeding and genetic alteration, community disruption, confinement, 
handling, fear, and painful procedures-and because AD research animals 
always die. It is also because the human disease is prevalent, frightening, 
and debilitating and its victims also always die from or with the disease. The 
animal-use ethical question involves a spectrum of viewpoints, ranging from 
no concern for the animals to strong objection to any harmful animal use for 
research purposes. Public surveys over the past few decades have shown a shift 
towards the latter position or towards restricting animal use to essential and 
unavoidable circumstances, the definition of which is also variable. But wher­
ever one stands on the animal-use ethical spectrum, hopefully all can agree 
that the conduct of frightening, painful, and lethal experiments on sentient 
beings-whether mice, dogs, or monkeys-is unacceptable when the research 
translates in no significant way to human benefits, despite decades of effort. 
The authors of this chapter have been animal researchers, and they have first­
hand knowledge that the process is unavoidably cruel, painful, unreliable, 
and ultimately unrewarding. Nonetheless, we have not argued that no useful 
knowledge ever results from animal experiments, but we have demonstrated 
that such knowledge is restricted in practical terms to the genetically manipu­
lated experimental species. That is, it is unreliable for human medicine and 
does not result in meaningful treatments for AD. 
In view of the billions of dollars of federal and private research support for 
AD, now more than one billion dollars annually of taxpayer funds alone, mean­
ingful clinical results are an ethical expectation. Yet, such results remain absent, 
and there are no current animal research approaches promising translational 
basic science revelations or improved drug development in the foreseeable fu­
ture. Spiraling costs related to basic science and clinical research, clinical diag­
nostics, acute and especially chronic patient care, caregiver support, and the 
economic consequences facing families, communities, and businesses are on 
track to decimate federal and private insurance programs and further impair 
economic productivity. 
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Arguably the most immediate ethical question regards accountability to 
AD patients, those at risk for AD, their families and communities. The costs 
of a failed animal research underpinning for AD are not limited to money 
spent and strained research resources, and include irretrievable losses in 
time, hope, and human lives. Of all the ethical accompaniments of AD ani­
mal research, the deferred and unrealized obligations to those impacted by 
AD, the persistence in pursuing a failed research model, the recurring hype 
surrounding drugs that cannot affect AD or its outcome, the advances pe­
rennially •�ust around the comer" are the real-world human consequences. 
As a corollary, preclinical researchers in the field have spent years or de­
cades performing productive bench work without contributing to improving 
quality of life, delaying disease progression, or prolonging the lives of AD 
patients. 
For now, and likely years ahead, there will be nothing more than the four 
largely inconsequential AD drugs currently available. Neurobiologist, George 
Perry, Dean of the College of Sciences at the University of Texas at San Anto­
nio, summed this up: "The field has known for over 10 years, probably 15 years, 
that the models were not Alzheimer disease and could not predict therapeu­
tic efficacy" (Begley, 2016). This paralyzing mindset must be overcome to gain 
ground on AD, and the replacement of animal research with human-relevant 
research methods is the path forward. 
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